Furthermore, low expression of YTHDF1 can reduce the sensitivity of cancer tissue to cisplatin was attributed to the Keap1-Nrf2-AKR1C1 axis (Kelch-like ECH-associated protein 1, NF-E2 p45-related factor 2 and antioxidant genes including aldo-keto reductases 1C1) (33). This evidence concerns the gene YTHDF1 and cancer.